GRCL Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 107923 min ago

@ CNY10.28

Ausgestellt: 14 Feb 2024 @ 21:48

Rendite: -0.29%

Vorheriges Signal: Feb 14 - 19:13

Vorheriges Signal: Verkaufen

Rendite: -0.48 %

Live Chart Being Loaded With Signals

Commentary (21 Feb 2024 @ 22:00):

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China...

Stats
Tagesvolumen	6.37M
Durchschnittsvolumen	1.46M
Marktkapitalisierung	989.87M
EPS	CNY0 ( 2024-03-11 )
Nächstes Ertragsdatum	( CNY0 ) 2024-05-13
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-10.57
ATR14	CNY0.215 (2.10%)

Volumen Korrelation

Lang: 0.31 (neutral)

Kurz: 0.24 (neutral)

Signal:(68.183) Neutral

Gracell Biotechnologies Korrelation

10 Am meisten positiv korreliert
ENPH	0.931
BLU	0.927
ATAI	0.922
NNOX	0.916
PTPI	0.915
RDHL	0.915
RXT	0.915
IMCC	0.91
PAVM	0.908
VORB	0.905

10 Am meisten negativ korreliert
ITMR	-0.929
OPNT	-0.929
AVEO	-0.925
VLYPP	-0.923
DVCR	-0.923
CIH	-0.918
BKCH	-0.916
FRGI	-0.915
EWEB	-0.907
MLCO	-0.901

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Gracell Biotechnologies Korrelation - Währung/Rohstoff

-0.17
( neutral )

0.64
( weak )

0.55
( weak )

0.12
( neutral )

0.51
( weak )

0.24
( neutral )

Gracell Biotechnologies Finanzdaten

Annual	2022
Umsatz:	CNY0
Bruttogewinn:	CNY0 (0.00 %)
EPS:	CNY-5.65

FY	2022
Umsatz:	CNY0
Bruttogewinn:	CNY0 (0.00 %)
EPS:	CNY-5.65

FY	2021
Umsatz:	CNY366 000
Bruttogewinn:	CNY0.00 (0.00 %)
EPS:	CNY-4.31

FY	2020
Umsatz:	CNY0.00
Bruttogewinn:	CNY0.00 (0.00 %)
EPS:	CNY-13.85

Financial Reports:

No articles found.

Gracell Biotechnologies

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.